JW (Cayman) Therapeutics (2126) Fundamentals 2026 — Revenue Analysis | SniperIQ

.68 on the HKSE. This SniperIQ fundamentals page covers JW (Cayman) Therapeutics's valuation, profitability (net margin -196.1%), revenue (¥276M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is JW (Cayman) Therapeutics's market cap?

JW (Cayman) Therapeutics (2126) has a market capitalization of approximately HK$700M, trading at HK

.68 on the HKSE. Market cap moves with the live share price.

What is JW (Cayman) Therapeutics's P/E ratio?

JW (Cayman) Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is JW (Cayman) Therapeutics?

JW (Cayman) Therapeutics runs a net profit margin of -196.1%, a gross margin of 43.1%, and an operating margin of -105.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does JW (Cayman) Therapeutics generate?

JW (Cayman) Therapeutics reported revenue of ¥276M for fiscal year 2025, with net income of -¥541M and earnings per share (EPS) of -1.3. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does JW (Cayman) Therapeutics pay a dividend?

JW (Cayman) Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is JW (Cayman) Therapeutics financially healthy?

JW (Cayman) Therapeutics carries a debt-to-equity ratio of 0.47x and a current ratio of 1.45x, with a market beta of 1.90. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is JW (Cayman) Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For JW (Cayman) Therapeutics (2126) the key facts are: market cap HK$700M, revenue ¥276M, 52-week range 1.4-6.44. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.